Vera Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Vera Therapeutics, Inc. (VERA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $236.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $120.00K, a 72.97% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $116.00K, a 74.62% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $113.00K, a 79.38% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $435.00K, a 12.30% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.45M, a 29.80% decline from fiscal 2024.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.06M, a 7.19% decline from fiscal 2023.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.22M, a 2.07% decline from fiscal 2022.
- Vera Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.27M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $236.00K 10-Q · filed 2026-08-10 | $349.00K derived: sum of 3 quarters · filed 2026-08-10 | $784.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $116.00K 10-Q · filed 2026-05-07 | $229.00K derived: sum of 2 quarters · filed 2026-05-07 | $664.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.11M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $548.00K derived: sum of 2 quarters · filed 2026-02-26 | $992.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.45M 10-K · filed 2026-02-26 |
| 2025-09-30 | $435.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $879.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.34M 10-Q · filed 2025-11-05 | $1.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $444.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $901.00K 10-Q · filed 2026-08-10 | $1.45M derived: sum of 3 quarters · filed 2026-08-10 | $1.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $457.00K 10-Q · filed 2026-05-07 | $1.00M derived: sum of 2 quarters · filed 2026-05-07 | $1.50M derived: sum of 3 quarters · filed 2026-05-07 | $2.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.04M derived: sum of 2 quarters · filed 2026-02-26 | $1.55M derived: sum of 3 quarters · filed 2026-02-26 | $2.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | $496.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $999.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.52M 10-Q · filed 2025-11-05 | $2.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.02M 10-Q · filed 2025-08-05 | $1.55M derived: sum of 3 quarters · filed 2026-02-26 | $2.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $517.00K 10-Q · filed 2025-05-07 | $1.05M derived: sum of 2 quarters · filed 2026-02-26 | $1.60M derived: sum of 3 quarters · filed 2026-02-26 | $2.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $532.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.65M derived: sum of 3 quarters · filed 2026-02-26 | $2.22M 10-K · filed 2026-02-26 |
| 2023-09-30 | $549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.11M derived: sum of 2 quarters · filed 2024-11-07 | $1.69M 10-Q · filed 2024-11-07 | $2.29M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.14M 10-Q · filed 2024-08-08 | $1.74M derived: sum of 3 quarters · filed 2024-08-08 | $2.30M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $579.00K 10-Q · filed 2024-05-10 | $1.17M derived: sum of 2 quarters · filed 2024-05-10 | $1.74M derived: sum of 3 quarters · filed 2024-05-10 | $2.29M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $595.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.16M derived: sum of 2 quarters · filed 2024-03-27 | $1.71M derived: sum of 3 quarters · filed 2024-03-27 | $2.27M 10-K · filed 2024-03-27 |
| 2022-09-30 | $561.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.11M derived: sum of 2 quarters · filed 2023-11-09 | $1.68M 10-Q · filed 2023-11-09 | $1.68M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.11M 10-Q · filed 2023-08-10 | $1.11M derived: sum of 3 quarters · filed 2023-08-10 | $1.11M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $564.00K 10-Q · filed 2023-05-11 | $564.00K derived: sum of 2 quarters · filed 2023-05-11 | $564.00K derived: sum of 3 quarters · filed 2023-05-11 | $564.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |